Get started
FIREBRICK PHARMA LIMITEDFF

FIREBRICK PHARMA LIMITED

0.066AUDD
0.0000.00%
As of today at 02:09 GMT
AUD
No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

FRE fundamentals

Key facts

Market capitalization‪14.82 M‬AUD
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)−0.01AUD
Founded2012
Employees (FY)—
CEOPeter Laurence Molloy
Websitefirebrickpharma.com
About

Firebrick Pharma Ltd. is a pharmaceutical company, which engages in the development and commercialization of nasal spray treatment for the common cold based around the potential of povidone-iodine as an antimicrobial agent. The company was founded by Peter Laurence Molloy and Stephen Goodall on April 12, 2012 and is headquartered in Melbourne, Australia.

Ownership
‪‪224.58 M‬‬
Free Float shares
‪‪147.19 M‬‬ (65.54%)
Closely held shares
‪‪77.39 M‬‬ (34.46%)
Free Float shares
‪‪147.19 M‬‬ (65.54%)
Closely held shares
‪‪77.39 M‬‬ (34.46%)
Capital structure
Market cap
‪‪14.82 M‬‬
Cash & equivalents
‪‪905.85 K‬‬
Enterprise value
‪‪13.92 M‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪14.82 M‬‬
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
63.00x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
—
Price to sales ratio (P/S)
63.00x
Valuation ratios
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪0.00‬
‪‪8.00 K‬‬
‪‪16.00 K‬‬
‪‪24.00 K‬‬
‪‪32.00 K‬‬
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−400,700.0%‬
‪−300,700.0%‬
‪−200,700.0%‬
‪−100,700.0%‬
‪−700.0%‬
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪‪−3.90 M‬‬
‪‪−2.60 M‬‬
‪‪−1.30 M‬‬
‪0.00‬
‪‪1.30 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−1.50 M‬‬
‪‪−1.00 M‬‬
‪‪−500.00 K‬‬
‪0.00‬
‪‪500.00 K‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−1.50 M‬‬
‪‪−1.00 M‬‬
‪‪−500.00 K‬‬
‪0.00‬
‪‪500.00 K‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Povidone-iodine (PVP-I)
By country
Period: 2024
Australia

Dividends

Dividend yield, history and sustainability

No dividends
FRE has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company

Debt level and coverage
H1 '23
H2 '23
H1 '24
H2 '24
H1 '25
‪‪−5.00 M‬‬
‪‪−2.50 M‬‬
‪0.00‬
‪‪2.50 M‬‬
‪‪5.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪400.00 K‬‬
‪‪800.00 K‬‬
‪‪1.20 M‬‬
‪‪1.60 M‬‬
Assets
Liabilities